About Glenmark Life Sciences
Glenmark Life Sciences is launching its IPO. The public offer comprises a fresh issue of equity shares worth Rs. 1,160 crores and offer for sale of 63 lakh equity shares by its parent company Glenmark Pharmaceuticals Ltd.
About the company:
Glenmark Life Sciences is a leading developer and manufacturer of Active Pharmaceutical Ingredients (APIs) catering to chronic therapeutic areas such as cardiovascular disease, central nervous system disorders, pain management, and diabetes, among others. As of December 31, 2020, the company had a portfolio of 120 molecules globally and sold its APIs in India as well as to multiple countries in Europe, North America, Latin America, Japan, and the rest of the world.
Financial Snapshot
| Financial Year Ended | Revenue (₹ Crores) | PAT (₹ Crores) | EPS (₹) |
| March 2019 | 886.87 | 195.59 | 24.64 |
| March 2020 | 1,549.30 | 313.10 | 29.04 |
| March 2021 | 1,885.98 | 351.58 | 32.61 |
How do I apply for the Glenmark IPO?
You can apply for the Glenmark Life Sciences IPO using any supported UPI app by following two steps:
- Enter your bid on Console
- Accept UPI mandate on your phone
On acceptance of the mandate, the bid amount will get blocked in your bank account. Click here to learn more.